Adding two weeks of continuous positive airway pressure for preterm infants in the hospital substantially improves lung ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

disease and prevented RSV hospitalizations among healthy preterm- and term infants, according to results of a phase IIb/III study. A single dose of clesrovimab reduced the incidence of RSV ...

Researchers from the Wesfarmers Center of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, ...

As cold and flu season continues in Vermont, the University of Vermont Medical Center is urging families to get their ...

The project will investigate the long-term severity of respiratory health in infants who contract Respiratory Syncytial Virus (RSV) and identify potential therapeutics that could improve pediatric ...

with FDA approval of Beyfortus for the prevention of RSV disease in infants. The US regulator has cleared the one-shot monoclonal antibody to prevent RSV lower respiratory tract disease in ...

An advisory panel for the U.S. Food and Drug Administration voted on Thursday in favor of recommending a vaccine — made by Pfizer — to protect infants from RSV, or Respiratory Syncytial Virus ...

MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-growing ...

Infants aged 2 years or younger, pregnant women and adults aged older than 50 years qualify for an FDA-approved RSV vaccine. Abrysvo for pregnant women had the highest administration rate since ...